报告时间：2019年5月21日（星期二），14:00-15:00

报告地点：会议中心二号会议室（204）

报告人：Prof. Venkatesan Renugopalakrishnan，Boston Children’s Hospital, Harvard Medical School & Northeastern University

　　报告摘要：

　　Biomarkers in serum and other physiological fluids provide footprints of a galore of diseases. As we enter the age of personalized precision medicine, ultra-sensitive monitoring of biomarkers in serum is an important first step. Today’s diagnostics demand pico molar sensitivity in the detection of biomarkers. Diagnostics constitutes a significant percentile of the burgeoning health care costs world-wide (in US ~3.5 Trillion, China approaching ~ 1 Trillion). Life style or genetically inherited diseases, especially diabetes, cardiovascular (CV) demand low cost, high throughput, throw away point of care devices to monitor serum glucose, cholesterol, triglyceride and HbA1c in the health management of the juvenile and aging population. Even for glucose monitoring, the challenges in obtaining sufficiently accurate and reliable measurements are so significant, none of them meet the stringent requirement of ISO and FDA. Because inaccurate systems bear the risk of false therapeutic decisions, rising health care costs, there is an urgent compelling need for significantly enhanced diabetes and CV monitoring systems for point of care applications. POC tests for other biomedically important biomarkers, especially renal failure (Creatine, kidney injury moleccule-1, with our collaborator Joseph V Bonventre, Brighams and Womens Hospital, Harvard Medical School), microRNA for early diagnosis of carcinoma, are generally even less accurate or non-existent.

　　The overall goal of the research in our laboratories at Harvard, Stanford, UC Berkeley, North Dakota State University, MIT, Toyo University, Saitama Prefecture, Japan, and Rice University, is to develop new sensor platforms that will provide increased sensitivity and accuracy in point of care situations. Graphene Fluorographene (7% fluorination), MoS2 based platforms decorated by a probe protein and anti-sense micro RNA enhances the sensitivity of pristine single layer graphene multi-fold and offers a very accurate determination of critical biomarkers in the blood and other body fluids including saliva. The proposed system uses advanced graphene, doped graphene. platform to transduce enzymatic binding into electrical signals using that can be read and processed by a stand-alone system or mobile devices. This approach will improve accuracy because it reduces operator errors, calibration problems, and strip-to-strip variability, while increasing sensor sensitivity/specificity with the option to use redundant sensors for improved statistical confidence. The central goal of Bioengineering Research Consortium, NIBIB, NCI is to develop multiplexed sensors that use a tiny drop of blood, saliva, placenta, sweat, cerebro-spinal fluid, amniotic fluid, bile, urine (20-50 μL) and quantify more than one clinically important analyte simultaneously and answer specific questions for diagnosis. The small sample size means that the devices can be used at the bedside, home, or laboratory. The proposed multiplexed sensor makes several measurements simultaneously which are analyzed together to determine a specific result with greater precision than a single sensor and more efficiently than a series of individual tests. These sensors will be evaluated at Children’s Hospital in Boston, Medical College of Wisconsin in collaboration with physicians. The combination of microfluidics with highly sensitive graphene-based sensors will allow measurements from small amounts of blood, i.e. finger sticks, so it will provide truly rapid bedside information. In addition, the graphene-sensors directly transduce the antibody- antigen interaction, enzyme-substrate reaction, and single-stranded double stranded RNAs properties, into an electronic measurement, which can be quickly determined without requiring laboratory time for ELISA, calorimetric assay and/or nucleic acid hybridization assay. For this type of research, novel sensors are probably more important than multiplexed measurements. Multiplex sensors are fundamental in emerging personalized precision medicine. 　　

　　报告人简介：

　　Prof. Venkatesan Renugopalakrishnan, a Biophysicist by formal training who has migrated to several interdisciplinary areas where basic science, nano, materials, and medical sciences overlap. Over the years, his research has turned its focus on graphene protein microfluidic sensors for applications in endocrinology, nephrology, neonatal pediatrics, biosolar perovskite cells, very high density protein based thin film and micro SD cards for mobile devices, smell receptors anchored on active carbon based platforms, biofuel cells, aquaporin biomimetic membranes for water recovery and desalination. Many of these are futuristic and likely to impact World economy. He teaches at the Harvard Medical School and Northeastern University. The fusion of protein engineering, nano fabrication, and materials science and engineering holds much promise in auguring a new era in point-of-care devices for self-monitoring, hospital use especially in continuous monitoring systems, reducing errors in diagnosis, and reducing the cost of health care. He is the author of approx. 300 papers including reviews, chapters, monographs and a member of academies, editorial boards, and boards of Corporations.　　

　　联系人：18T4 白雪

　　联系电话：84379390